Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Parkinson's Disease (PD) Drugs Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Parkinson's Disease (PD) Drugs Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Dopamine Agonist
      • 1.3.3 Monoamine Oxidase Inhibitors
      • 1.3.4 Acetylcholinesterase Inhibitors
      • 1.3.5 Glutamate Inhibitors
    • 1.4 Market Segment by Application
      • 1.4.1 Global Parkinson's Disease (PD) Drugs Market Share by Application (2019-2025)
      • 1.4.2 Hospital
      • 1.4.3 Family
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Parkinson's Disease (PD) Drugs Market Size
      • 2.1.1 Global Parkinson's Disease (PD) Drugs Revenue 2014-2025
      • 2.1.2 Global Parkinson's Disease (PD) Drugs Sales 2014-2025
    • 2.2 Parkinson's Disease (PD) Drugs Growth Rate by Regions
      • 2.2.1 Global Parkinson's Disease (PD) Drugs Sales by Regions 2014-2019
      • 2.2.2 Global Parkinson's Disease (PD) Drugs Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Parkinson's Disease (PD) Drugs Sales by Manufacturers
      • 3.1.1 Parkinson's Disease (PD) Drugs Sales by Manufacturers 2014-2019
      • 3.1.2 Parkinson's Disease (PD) Drugs Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Parkinson's Disease (PD) Drugs Revenue by Manufacturers (2014-2019)
      • 3.2.2 Parkinson's Disease (PD) Drugs Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Parkinson's Disease (PD) Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.3 Parkinson's Disease (PD) Drugs Price by Manufacturers
    • 3.4 Key Manufacturers Parkinson's Disease (PD) Drugs Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Parkinson's Disease (PD) Drugs Market
    • 3.6 Key Manufacturers Parkinson's Disease (PD) Drugs Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Dopamine Agonist Sales and Revenue (2014-2019)
      • 4.1.2 Monoamine Oxidase Inhibitors Sales and Revenue (2014-2019)
      • 4.1.3 Acetylcholinesterase Inhibitors Sales and Revenue (2014-2019)
      • 4.1.4 Glutamate Inhibitors Sales and Revenue (2014-2019)
    • 4.2 Global Parkinson's Disease (PD) Drugs Sales Market Share by Type
    • 4.3 Global Parkinson's Disease (PD) Drugs Revenue Market Share by Type
    • 4.4 Parkinson's Disease (PD) Drugs Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Parkinson's Disease (PD) Drugs Sales by Application

    6 United States

    • 6.1 United States Parkinson's Disease (PD) Drugs Breakdown Data by Company
    • 6.2 United States Parkinson's Disease (PD) Drugs Breakdown Data by Type
    • 6.3 United States Parkinson's Disease (PD) Drugs Breakdown Data by Application

    7 European Union

    • 7.1 European Union Parkinson's Disease (PD) Drugs Breakdown Data by Company
    • 7.2 European Union Parkinson's Disease (PD) Drugs Breakdown Data by Type
    • 7.3 European Union Parkinson's Disease (PD) Drugs Breakdown Data by Application

    8 China

    • 8.1 China Parkinson's Disease (PD) Drugs Breakdown Data by Company
    • 8.2 China Parkinson's Disease (PD) Drugs Breakdown Data by Type
    • 8.3 China Parkinson's Disease (PD) Drugs Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Parkinson's Disease (PD) Drugs Breakdown Data by Company
    • 9.2 Rest of World Parkinson's Disease (PD) Drugs Breakdown Data by Type
    • 9.3 Rest of World Parkinson's Disease (PD) Drugs Breakdown Data by Application
    • 9.4 Rest of World Parkinson's Disease (PD) Drugs Breakdown Data by Countries
      • 9.4.1 Rest of World Parkinson's Disease (PD) Drugs Sales by Countries
      • 9.4.2 Rest of World Parkinson's Disease (PD) Drugs Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Boehringer Ingelheim
      • 10.1.1 Boehringer Ingelheim Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Parkinson's Disease (PD) Drugs
      • 10.1.4 Parkinson's Disease (PD) Drugs Product Introduction
      • 10.1.5 Boehringer Ingelheim Recent Development
    • 10.2 GlaxoSmithKline
      • 10.2.1 GlaxoSmithKline Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Parkinson's Disease (PD) Drugs
      • 10.2.4 Parkinson's Disease (PD) Drugs Product Introduction
      • 10.2.5 GlaxoSmithKline Recent Development
    • 10.3 Novartis
      • 10.3.1 Novartis Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Parkinson's Disease (PD) Drugs
      • 10.3.4 Parkinson's Disease (PD) Drugs Product Introduction
      • 10.3.5 Novartis Recent Development
    • 10.4 Teva Pharmaceutical Industries
      • 10.4.1 Teva Pharmaceutical Industries Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Parkinson's Disease (PD) Drugs
      • 10.4.4 Parkinson's Disease (PD) Drugs Product Introduction
      • 10.4.5 Teva Pharmaceutical Industries Recent Development
    • 10.5 AbbVie
      • 10.5.1 AbbVie Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Parkinson's Disease (PD) Drugs
      • 10.5.4 Parkinson's Disease (PD) Drugs Product Introduction
      • 10.5.5 AbbVie Recent Development
    • 10.6 Abital Pharma
      • 10.6.1 Abital Pharma Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Parkinson's Disease (PD) Drugs
      • 10.6.4 Parkinson's Disease (PD) Drugs Product Introduction
      • 10.6.5 Abital Pharma Recent Development
    • 10.7 Addex Therapeutics
      • 10.7.1 Addex Therapeutics Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Parkinson's Disease (PD) Drugs
      • 10.7.4 Parkinson's Disease (PD) Drugs Product Introduction
      • 10.7.5 Addex Therapeutics Recent Development
    • 10.8 Biogen
      • 10.8.1 Biogen Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Parkinson's Disease (PD) Drugs
      • 10.8.4 Parkinson's Disease (PD) Drugs Product Introduction
      • 10.8.5 Biogen Recent Development
    • 10.9 Eisai
      • 10.9.1 Eisai Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Parkinson's Disease (PD) Drugs
      • 10.9.4 Parkinson's Disease (PD) Drugs Product Introduction
      • 10.9.5 Eisai Recent Development
    • 10.10 Eli Lilly
      • 10.10.1 Eli Lilly Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Parkinson's Disease (PD) Drugs
      • 10.10.4 Parkinson's Disease (PD) Drugs Product Introduction
      • 10.10.5 Eli Lilly Recent Development
    • 10.11 F. Hoffmann-La Roche
    • 10.12 H. Lundbeck
    • 10.13 Impax Laboratories
    • 10.14 Kyowa Hakko Kirin
    • 10.15 Otsuka Pharmaceutical
    • 10.16 Pfizer

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Parkinson's Disease (PD) Drugs Sales Channels
      • 11.2.2 Parkinson's Disease (PD) Drugs Distributors
    • 11.3 Parkinson's Disease (PD) Drugs Customers

    12 Market Forecast

    • 12.1 Global Parkinson's Disease (PD) Drugs Sales and Revenue Forecast 2019-2025
    • 12.2 Global Parkinson's Disease (PD) Drugs Sales Forecast by Type
    • 12.3 Global Parkinson's Disease (PD) Drugs Sales Forecast by Application
    • 12.4 Parkinson's Disease (PD) Drugs Forecast by Regions
      • 12.4.1 Global Parkinson's Disease (PD) Drugs Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Parkinson's Disease (PD) Drugs Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra.
      The emergence of gene therapy to reverse the progression of PD is one of the key trends that will gain traction in the market for parkinsons drugs throughout the estimated period.
      In 2019, the market size of Parkinson's Disease (PD) Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Parkinson's Disease (PD) Drugs.

      This report studies the global market size of Parkinson's Disease (PD) Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Parkinson's Disease (PD) Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Boehringer Ingelheim
      GlaxoSmithKline
      Novartis
      Teva Pharmaceutical Industries
      AbbVie
      Abital Pharma
      Addex Therapeutics
      Biogen
      Eisai
      Eli Lilly
      F. Hoffmann-La Roche
      H. Lundbeck
      Impax Laboratories
      Kyowa Hakko Kirin
      Otsuka Pharmaceutical
      Pfizer

      Market Segment by Product Type
      Dopamine Agonist
      Monoamine Oxidase Inhibitors
      Acetylcholinesterase Inhibitors
      Glutamate Inhibitors

      Market Segment by Application
      Hospital
      Family

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Parkinson's Disease (PD) Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Parkinson's Disease (PD) Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Parkinson's Disease (PD) Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now